ReviewPharmacoepidemiology and drug safety2024
Core Concepts in Pharmacoepidemiology: New-User Designs.
Review in Pharmacoepidemiology and drug safety, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Response to "Temporality before complexity in JAK inhibitor cardiovascular safety analyses".Clinical rheumatology · 2026Article
- Active and Non-Active Comparators Yield Different Estimates of the Association Between Proton Pump Inhibitor Use and Recorded Mortality During Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.Pharmacoepidemiology and drug safety · 2026Article
- Article
- Risk of gastrointestinal bleeding with gabapentin versus duloxetine in older adults with neuropathic pain: a target trial emulation cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.Diabetes, obesity & metabolism · 2026Article
- Menopausal hormone therapy and risk of liver cancer in a Swedish population-based cohort study.Journal of the National Cancer Institute · 2026Article
- Comment on: Does Aspirin Use Influence Rates of Pseudoarthrosis After Anterior Cervical Discectomy and Fusion?Global spine journal · 2026Article
- Long-Term Cardiovascular Risks of Anticholinergic Versus Non-Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction.Pharmacoepidemiology and drug safety · 2026Article
- Core Concepts in Pharmacoepidemiology-Round 3: Call for Writing Groups.Pharmacoepidemiology and drug safety · 2026Article
- Practice disparities in palliative radiation therapy for bone metastases: insights from the Shizuoka Kokuho database study.Japanese journal of radiology · 2026Article
- Gastrointestinal Surgery Status and the Risks of Ischemic Stroke and Safety Outcomes With Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation: A Nationwide Population-Based Cohort Study.Journal of stroke · 2026Article
- Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.Ophthalmology. Retina · 2026Article
- Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk.Journal of diabetes · 2026Article
- Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.Scientific reports · 2026Article
- Pediatric Somatic and Psychiatric Hospital Contacts in Denmark: A National Overview of Risk Factors, Admissions, and Mortality.Acta psychiatrica Scandinavica · 2026Article
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.Nature medicine · 2026Article
- Association Between Sodium-Glucose Cotransporter-2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
- Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study.Archives of osteoporosis · 2025Article
- Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study.Diabetes, obesity & metabolism · 2025Article
- The risk of fracture among women starting selective serotonin reuptake inhibitors.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this article, we review the history and key reasons for new-user comparisons in pharmacoepidemiology, highlighting the target trial framework as a unifying framework. We describe three distinct pharmacoepidemiological new-user study designs: (1) new-user versus non-user; (2) active comparator new-user; (i.e., ACNU) and (3) prevalent new-user (i.e., PNU) designs, and discuss how each relates to key issues of defining time zero, choosing appropriate comparator groups, and potential sources of bias they do and do not account for. We use a clinical example of hormone replacement therapy and the risk of coronary heart disease to illustrate practical considerations surrounding the application of the three designs presented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.